COVID-19 (Coronavirus Disease 2019)COVID-19NCT07504341
Physiological Finding in Management of COVID 19 Patients
An observational study of COVID-19 (Coronavirus Disease 2019), run by St. Martin De Porress Hospital at 2 sites in Taiwan.
Trial summary
This study utilizes physiological indicators of COVID-19 patients as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. This study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- COVID-19 (Coronavirus Disease 2019)
- What is being tested?
- physiological parameters
- How many people
- 15,000 participants
- Where
- 2 sitesTaiwan
- Study dates
- Apr 2026to 31 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: The COVID-19 patient received treatment at the hospital between May 2022 and March 2027 from emergency room, OPD
Who may be able to join
- Reviewing the patient's medical history, the primary focus was on hospital records and existing physiological parameters such as blood pressure, heart rate, respiratory rate, and level of consciousness. The patient received treatment at the hospital between May 2022 and March 2027
Who cannot join
- Excluding patients with incomplete clinical data or missing information in their medical records.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Taiwan2 sites, 2 recruiting
- Recruiting
St. Martin De Porres Hospital
Chiayi City, 60069
- Recruiting
St. Martin De Porres Hospital
Tainan, 60069
Chia-Hsi Chen, physician, 5-2756000 ext. 3708, urologist3509@gmail.com
Chia-Hsi Chen, physician, 5-2756000-3708 ext. 3708, urologist3509@gmail.com
About this study
Official title: The Combined Usage of Clinical Physiological Finding in Management of COVID 19 Patients
This study utilizes physiological indicators of COVID-19 patients as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. This study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early response and medication.
Read the detailed description
This study utilizes physiological indicators of COVID-19 patients, such as blood pressure, heart rate, respiratory rate, and level of consciousness, to develop Shock Index (SI), Mordified Shock Index (MSI), Age Shock Index (Age SI), Age Mordified Shock Index (Age MSI), and Respiratory Adjusted Shock Index (RASI), as well as other physiological indicators, as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. For patients with mild to severe illness, and in response to the shortage of manpower during a large influx of emergency patients, this study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early response and medication.
- Conditions
- COVID-19 (Coronavirus Disease 2019)
- Being tested
- physiological parameters
- Keywords
- COVID-19, shock index, mordified shock index, Age shock index, respiratory adjusted shock index
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
physiological parametersOther
systolic blood pressure, diastolic blood pressure , heart rate, respiratory rate , GCS
| Study group | Role | What they receive |
|---|---|---|
| COVID-19 patient | The COVID-19 patients were devided into admission ,OPD groups Receives: Other: physiological parameters |
What is being measured
The primary outcome is the main question the study is designed to answer.
Shock index(SI) in the management of COVID -19
SI= heart rate / systolic blood pressre
Measured: 2022 May to 2027 March
Mordified shock index(MSI) in the management of COVID -19
MSI=heart rate / mean arterial pressure
Measured: 2022 May to 2027 March
Age shock index(Age SI) in the management of COVID -19
Age shock index =Age x (heart rate / systolic blood pression)
Measured: 2022 May to 2027 March
Respiratory adjusted shock index (RASI) in the management of COVID-19
Respiratory adjusted shock index =(heart rate/systolic blood pression) x (repiratory rate/10)
Measured: 2022 may to 2027 March
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Mar 2026
- Study startApr 2026 (estimated)
- Primary completion11 Mar 2027 (estimated)
- Study completion31 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19 (Coronavirus Disease 2019)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 15,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- St. Martin De Porress Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chia-hsi Chen, St. Martin De Porress Hospital
- Investigators
- Chia-Hsi Chen, Physician, Principal investigator, St. Martin De Porress Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07504341
- Sponsor's protocol ID
- 26B-005
- Other IDs
- 26B-005
- Acronym
- COVID-19
- Status last verified
- Mar 2026
- First submitted
- 16 Mar 2026
- Last updated
- 31 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Under the privacy of patients the data of medical record can't be shared with others researchers.
Study at a glance
From the registry record, last updated by the sponsor on 31 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Combined Usage of Clinical Physiological Finding in Management of COVID 19 Patients
- ClinicalTrials.gov ID
- NCT07504341
- Acronym / sponsor ID
- COVID-19 / 26B-005
- Conditions
- COVID-19 (Coronavirus Disease 2019)
- Keywords
- COVID-19, shock index, mordified shock index, Age shock index, respiratory adjusted shock index
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 15,000 participants (estimated)
- Lead sponsor
- St. Martin De Porress HospitalUniversity, hospital or other
- Study start
- Apr 2026 (estimated)
- Primary completion
- 11 Mar 2027 (estimated)
- Study completion
- 31 Mar 2027 (estimated)
- First posted
- 31 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study utilizes physiological indicators of COVID-19 patients as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. This study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early response and medication.
Detailed description
This study utilizes physiological indicators of COVID-19 patients, such as blood pressure, heart rate, respiratory rate, and level of consciousness, to develop Shock Index (SI), Mordified Shock Index (MSI), Age Shock Index (Age SI), Age Mordified Shock Index (Age MSI), and Respiratory Adjusted Shock Index (RASI), as well as other physiological indicators, as tools for assessing, tracking, worsening, and improving the clinical symptoms of COVID-19 patients. For patients with mild to severe illness, and in response to the shortage of manpower during a large influx of emergency patients, this study employs simple and easy-to-use assessment methods, which can be further aided by artificial intelligence technology to facilitate early response and medication.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| COVID-19 patient | – | Other: physiological parametersThe COVID-19 patients were devided into admission ,OPD groups |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- The COVID-19 patient received treatment at the hospital between May 2022 and March 2027 from emergency room, OPD
Key inclusion criteria (1 listed)
- Reviewing the patient's medical history, the primary focus was on hospital records and existing physiological parameters such as blood pressure, heart rate, respiratory rate, and level of consciousness. The patient received treatment at the hospital between May 2022 and March 2027
Key exclusion criteria (1 listed)
- Excluding patients with incomplete clinical data or missing information in their medical records.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| physiological parameterssystolic blood pressure, diastolic blood pressure , heart rate, respiratory rate , GCS | Other | COVID-19 patient |
Primary outcome
Shock index(SI) in the management of COVID -19
Time frame: 2022 May to 2027 March
SI= heart rate / systolic blood pressre
Mordified shock index(MSI) in the management of COVID -19
Time frame: 2022 May to 2027 March
MSI=heart rate / mean arterial pressure
Age shock index(Age SI) in the management of COVID -19
Time frame: 2022 May to 2027 March
Age shock index =Age x (heart rate / systolic blood pression)
Respiratory adjusted shock index (RASI) in the management of COVID-19
Time frame: 2022 may to 2027 March
Respiratory adjusted shock index =(heart rate/systolic blood pression) x (repiratory rate/10)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Mar 2026.
- Individual participant dataSharing planned: No. Under the privacy of patients the data of medical record can't be shared with others researchers.
Related trials for COVID-19 (Coronavirus Disease 2019)
RecruitingPhase 3
A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease
SARS-CoV-2
RecruitingObservational study
Viral Infections in Healthy and Immunocompromised Hosts
Anogenital Herpes, COVID-19
Active, not recruiting
Motivational Interviewing Intervention for Families With Overweight and Obesity
Obesity & Overweight
Active, not recruiting
Lupus Education Alliance Program
Systemic Lupus Erythematosus, COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chia-Hsi Chen, Physician principal investigator
St. Martin De Porress Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19 (Coronavirus Disease 2019), run by St. Martin De Porress Hospital at 2 sites in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 31 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Chia-Hsi Chen, Physician (886-5-2756000 ext. 3708, urologist3509@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Shock index(SI) in the management of COVID -19 (time frame: 2022 May to 2027 March). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2026.